This activity aims to enable the learner to apply knowledge of the benefits and applications of paper and electronic infusion logs.
Alnylam reports the latest Phase 2 study showed that the safety and tolerability associated with fitusiran “remains encouraging.”
If effective, the therapy prompts the sustained production of FVIII and enhanced protection from bleeds.
Results showed a statistically significant and clinically meaningful reduction in bleed rate, reports states.
NHF, HFA, the Hemophilia Alliance and Coalition for Hemophilia B are united in their opposition to the Graham-Cassidy-Heller-Johnson Bill because of its damaging impact on our community and urge the Senate to reject these harmful policies.
Call TODAY and tell your Senator to vote NO on BCRA!
This activity will cover the three major steps in normal hemostasis and the basics of treatment and management of patients with hemophilia.
FDA approves the Biologics License Application (BLA) for REBINYN®
New therapy failed to show significant efficacy in a phase I/II clinical study.
A wider perspective on the "burden" hemophilia patients place on health plans.
eNewsletter Sign Up
Steps for Living
Victory for Women
Unite for Bleeding Disorders Walk
Donate Your Car